Medical Science Liaison - West
About the job
- A master's degree (MPH or equivalent) with at least 3 years of relevant clinical or therapeutic experience; a doctorate-level degree (MD, PharmD, or PhD) is preferred.
- Three to five years of MSL experience, primarily involving rare diseases, field-based scientific exchange, and/or clinical trial support.
- Therapeutic-area and/or hereditary angioedema expertise is preferred.
- Availability to travel 80% of the time, including weekends and holidays.
- Ability to establish credible, long-lasting professional relationships and engage respectfully and professionally.
- Personal accountability, ownership, continuous performance improvement, and operational excellence.
- Ability to exchange scientific ideas effectively with key opinion leaders and colleagues, and present scientific and medical data to small and large audiences.
- In-depth therapeutic competency and expertise in the science of the designated disease state, with the ability to maintain knowledge of assigned disease areas and products.
- Ability to manage challenging conversations and handle objections.
- Ability to work effectively in person and/or virtually, listen effectively, and build relationships while advancing appropriate scientific-exchange opportunities.
- Ability to work effectively on multidisciplinary teams and collaborate with R&D, Commercial, and other internal functions.
- Strong written and verbal communication, leadership, and influencing skills.
- Ability to plan, manage, and prioritize multiple projects independently, think innovatively and strategically, and demonstrate resilience and flexibility.
- Knowledge of applicable pharmaceutical guidelines and regulations, including ICH, GCP, PhRMA, DOJ, OIG, R&D Code of Ethical Practices, and company policies.
- Above-average computer skills, including MS Office and databases.
- Clean and valid driver's license.
- Serve as the field-based extension of the Medical Affairs team, with field-based activities expected to comprise more than 80% of MSL responsibilities.
- Identify scientific-exchange needs of key opinion leaders, investigators, and other patient-care stakeholders; establish professional relationships; provide scientific expertise; and liaise with Medical, Clinical Development/Operations, and external partners.
- Communicate and educate about the product portfolio compliantly to meet key customers' educational and professional needs, and respond to scientific-exchange requests.
- Support the design and implementation of scientific programs with external experts and Global Medical Affairs.
- Support local team disease-area and product knowledge through scientific training, and maintain expertise in relevant disease areas and MSL best practices.
- Build and maintain professional relationships with external stakeholders to expand research, advisory, and educational partnerships through appropriate scientific exchange.
- Develop peer-to-peer scientific relationships with thought leaders in healthcare, academia, payer, and government organizations according to territory plans and stakeholder requests; manage strategic scientific partnerships and scientific exchange.
- Provide scientific liaison support to investigators involved in interventional or observational studies and investigator-sponsored research, and provide scientific exchange and appropriate support to payer organizations.
- Serve as a liaison between healthcare professionals and Medical Affairs; facilitate individual and group scientific interactions; participate in KOL/HCP planning; and maintain accurate, timely, and compliant KOL/HCP plans and medical customer relationship management records.
- Maintain awareness of internal and external information sources supporting scientific exchange and coordinate high-quality interactions between those resources and external customers.
- Respond within defined timelines and quality standards to unsolicited inquiries referred to Global Medical Affairs, and forward adverse-event reports according to company policy.
- Support responses to unique inquiries, including presentation of scientific evidence and medical education.
- Present clinical and disease-state information to key opinion leaders, medical advisors, formulary decision-makers, and other healthcare professionals.
- Ensure fair, balanced, and non-misleading scientific exchange with healthcare professionals.
- Serve as a scientific resource at assigned medical, scientific, and patient advocacy conferences; conduct therapeutic training for Sales and Medical colleagues upon request.
- Communicate key medical insights from stakeholders to inform medical-strategy refinement; gather customer insights and organize advisory boards to obtain external feedback.
- Provide scientific input and participate in local medical and cross-functional initiatives; provide field-based medical support to clinical research programs, registries, and investigator-sponsored research processes.
- Under Medical Affairs leadership, provide scientific support for company-sponsored meetings and participate in internal project teams as directed.
- Ensure medical activities align with industry and company compliance and regulatory standards, policies, and regulations.
- Develop Medical Affairs standard operating procedures and policy guidance documents, and provide active medical support for cross-functional policy resources.
- Therapeutic-area and/or hereditary angioedema expertise.
- Doctorate-level degree (MD, PharmD, or PhD).
About the company
Pharvaris develops oral medications aimed at treating hereditary angioedema (HAE) and other bradykinin B2 receptor–mediated conditions. Its main focus is discovery and development of novel oral bradykinin B2 receptor antagonists that patients can take by mouth rather than by injection. The products work by blocking the bradykinin B2 receptor, which helps reduce or prevent swelling associated with these rare disorders. This approach sets Pharvaris apart from many current therapies that require injections, offering a convenient alternative for patients. The company operates in the clinical-stage biopharmaceutical space, pursuing regulatory approval and eventual commercialization of its oral therapies. Pharvaris’ goal is to provide effective, easier-to-use treatments that improve patient choice and quality of life for people with rare disease conditions.
Company Size
51-200
Company Stage
IPO
Headquarters
Leiden, Netherlands
Founded
2015
Get referred to Pharvaris
See people who can refer or advise you
Simplify's Take
What believers are saying
- September 8, 2026 CHAPTER-3 met its primary endpoint with 83% attack-rate reduction.
- FDA accepted the IR NDA July 6, 2026; PDUFA lands April 23, 2027.
- Cash reached €318 million on June 30, 2026, after a $132.3 million offering.
What critics are saying
- Pharvaris remains clinical-stage until 2027 approvals; one regulatory miss kills commercialization.
- Takeda's Takhzyro, Kalbitor, and hereditary-angioedema generics already defend entrenched prescribers.
- CREAATE and CHAPTER-4 dependence concentrates value in deucrictibant; safety setbacks would crater the stock.
What makes Pharvaris unique
- Deucrictibant targets bradykinin B2 receptors with oral dosing, unlike injected HAE therapies.
- CHAPTER-3 enrolled 85 patients across 21 countries, spanning HAE types 1, 2, and normal C1-INH.
- Pharvaris pairs on-demand IR and prophylactic XR formulations from one molecule.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Flexible Work Hours
Hybrid Work Options
Growth & Insights and Company News
6 month growth
0%1 year growth
-2%2 year growth
0%Key approvals, positive study results and a partnership deal to fast track new medications. 11.09.2026 The US Food and Drug Administration and the European Medicines Agency have granted two biotechs with Fast Track designation and Orphan Drug designation, respectively for therapies targeting ventilator-associated bacterial pneumonia and thymic epithelial tumours. Windward Bio and Pharvaris announced postive results from late-stage clinical trials. A new strategic collaboration for Avrios Therapeutics will see the company advance its AVR-001, an advanced preclinical gene therapy candidate for certain familial forms of amyotrophic lateral sclerosis. BioVersys, a multi-asset biotech company focused on the development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its lead candidate BV100 under the Qualified Infectious Disease Product (QIDP) designation. BV100 is currently being advanced for the treatment of ventilator-associated bacterial pneumonia (VABP) and hospital-acquired bacterial pneumonia (HABP) caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). BV100 possesses a novel mode of action via uptake via the siderophore pathway in Acinetobacter, providing a much-needed novel non-β-lactam therapy for this infection. BV100 is currently studied in two clinical trials: the pivotal Phase 3 global registrational trial, RIV-TARGET and the open-label Phase 2b differentiation trial, RIV-CARE in collaboration with ADVANCE-ID. These studies follow the successful Phase 2 study that showed BV100 had an overall 50% reduction in mortality compared with the best available therapy. In 2019, BV100 received the Qualified Infectious Disease Product (QIDP) Designation by the U.S. FDA. With the Fast Track designation, BioVersys can benefit from more frequent interactions with the FDA, increased communication on clinical trial design and data requirements, and eligibility for rolling review. EU Orphan Drug Designation for Torqur's thymic epithelial Torqur AG, a Swiss Rockets company advancing innovative clinical-stage treatments for oncology and dermatology, announced that the European Commission has granted orphan drug designation (ODD) for bimiralisib for the treatment of thymic epithelial tumours - severe and life-threatening cancers that lacks effective treatment options, are chronically debilitating due to their association with severe autoimmune comorbidities, such as myasthenia gravis, and they have the potential to progress into refractory disease. Receiving the EU ODD follows a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP), marking bimiralisib's third orphan drug designation, and its first in a solid tumour indication, building on the company's broader oral bimiralisib oncology pipeline. An EU ODD reflects the intention to diagnose, prevent or treat a life-threatening or chronically debilitating condition affecting not more than five in 10 thousand people in the Community when the application is made. The ODD recognizes the potential of bimiralisib to address the needs of patients affected by this devastating disease. Orphan designation in the EU provides access to protocol assistance and reduced regulatory fees during development and, upon marketing authorisation, up to ten years of market exclusivity in the designated indication. Windward Bio: positive Phase 2 results of WIN378 in asthma Windward Bio, a clinical-stage biotechnology company developing ultra-long-acting antibodies for patients with serious respiratory and dermatologic diseases, announced positive interim results from the Phase 2 portion of the POLARIS-1 clinical trial evaluating twice-yearly dosing of WIN378 in asthma. The Phase 2 portion of the study is designed to evaluate the pharmacokinetics, safety, immunogenicity and pharmacodynamic activity of WIN378 in patients with uncontrolled, moderate-to-severe asthma. The study also evaluates the effects of WIN378 on lung function and biomarkers of airway inflammation and informed dose selection for Phase 3 development. The Phase 2 portion of the study enrolled a total of 147 patients, exceeding the initial enrollment target of 120 patients, with the interim analysis conducted on the first 98 patients. The interim analysis demonstrated favorable safety and clinically meaningful effects across key measures of lung function and inflammation in asthma. Two twice-yearly doses have been selected for the Phase 3 portion of POLARIS-1 which is designed to evaluate the effect of WIN378 on annualized asthma exacerbation rate and other key efficacy measures in patients with severe asthma. The Phase 3 portion of the study has been initiated, and a second Phase 3 study, POLARIS-2, is planned to begin in the first half of 2027. Pharvaris: positive Phase 3 topline data in all three types of HAE Pharvaris, a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced statistically significant and clinically meaningful topline results of the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release (XR) tablet for the prevention of HAE attacks. The primary endpoint and all secondary efficacy endpoints were met with statistical significance. Data from the CHAPTER-3 study will serve as the basis for marketing authorization applications, which are planned to be submitted starting in the first half of 2027. HAE is a complex, rare, life-long genetic condition with significant burden from recurrent, unpredictable, disabling, and potentially life-threatening attacks of swelling affecting various body parts. Common attack locations include the extremities, face and neck, abdomen, and larynx. If untreated, HAE attacks can last multiple days. HAE affects all genders and ethnicities. Different forms of HAE are currently recognized and genetically identifiable due to their pathogenesis. Avrion Therapeutics enters strategic collaboration to advance AV-001 Lausanne-based Avrion Therapeutics focused on the developing transformative therapies for ALS and other neurodegenerative diseases, together with Institut Charcot, an initiative of ARSLA and ReMedys Foundation have signed a memorandum of understanding setting out a collaboration to advance AVR-001, an advanced preclinical gene therapy candidate for certain familial forms of amyotrophic lateral sclerosis (ALS) associated with mutations in SOD1. AVR-001 arises from research led by Dr. Bernard Schneider at EPFL, is jointly developed by ReMedys and Avrion, and will be included in Institut Charcot's integrated translational pipeline. The collaboration brings together ARSLA's patient-community perspective, Institut Charcot's scientific network, ReMedys' translational development expertise, and Avrion's gene therapy capabilities. Together, the partners aim to move the AVR-001 program towards clinical evaluation. 0Comments.
Pharvaris, a late-stage biopharmaceutical company developing oral treatments for bradykinin-mediated angioedema, reported second quarter 2026 financial results. The company held €318 million in cash and cash equivalents as of 30 June 2026. The FDA is reviewing Pharvaris' New Drug Application for deucrictibant IR, with a PDUFA date of 23 April 2027. The EMA validated the marketing authorisation application in July 2026. Pharvaris expects topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for hereditary angioedema prophylaxis, in the third quarter of 2026. Enrolment continues in CREAATE, a pivotal study for acquired angioedema treatment. The company closed a $132 million underwritten offering in May, extending its cash runway into 2028. Second quarter loss was €47.8 million, with R&D expenses of €35.0 million and G&A expenses of €15.8 million.
Pharvaris NV - FDA sets PDUFA action date for Deucrictibant IR NDA as April 23, 2027. Monday, Jul 6, 2026 6:50 am ET 1min read The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2027, for the New Drug Application (NDA) of deucrictibant immediate-release (IR) for the on-demand treatment of hereditary angioedema (HAE) attacks. This date marks the target by which the FDA aims to complete its review of the application, which is expected to be submitted in the first half of 2026. Pharvaris, a late-stage biopharmaceutical company, has been preparing the NDA dossier based on data from the RAPIDe-3 and RAPIDe-2 trials. The RAPIDe-3 study, a pivotal global Phase 3 trial, demonstrated that deucrictibant IR met its primary endpoint, with median time to onset of symptom relief of 1.28 hours, significantly faster than placebo. The company also plans to present additional data from these trials at upcoming medical congresses. The NDA filing is part of Pharvaris' broader strategy to commercialize deucrictibant for both on-demand and prophylactic treatment of HAE attacks. The company remains on track to submit the NDA in 1H2026, with clear timeline for regulatory review provided by the PDUFA date. Pharvaris also continues to advance its clinical development programs, including the ongoing CREAATE study for AAE-C1INH and the CHAPTER-3 trial for long-term prophylaxis of HAE attacks, with topline data expected in the third quarter of 2026. The company's cash runway extends into the first half of 2027, supporting its current development and commercialization efforts. The FDA's action date reflects the agency's prioritization of the application and provides a key milestone for Pharvaris as it moves toward potential regulatory approval and market launch of deucrictibant IR for HAE.
Pharvaris has priced an underwritten offering of 3,874,664 ordinary shares at $29.68 per share, expecting gross proceeds of approximately $115 million before underwriting discounts and commissions. The biopharmaceutical company has granted underwriters a 30-day option to purchase an additional 581,199 shares. The late-stage company is developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency. Morgan Stanley, Leerink Partners, Cantor and Wells Fargo Securities are acting as joint book-running managers. The offering is expected to close around 11 May 2026, subject to customary closing conditions. Shares are being offered through an effective shelf registration statement filed with the US Securities and Exchange Commission.
A director at Pharvaris N.V. sold 7,100 shares worth approximately $213,000 through a pre-scheduled Rule 10b5-1 trading plan, according to an SEC filing. The sale represents just 1.8% of director Johannes Schikan's direct holdings, leaving him with 388,067 shares valued at around $10.59 million. The transaction marks Schikan's only sale in the past year and was executed under a pre-arranged plan, indicating planned liquidity management rather than a change in outlook. No indirect holdings or derivative securities were involved in the transaction. Pharvaris, valued at $1.87 billion, is a clinical-stage biopharmaceutical company developing oral therapies for hereditary angioedema. The company's pipeline includes PHA121, PHVS416 and PHVS719, targeting various treatment approaches for the rare disease.